FDA warned Korean Fillers that its website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers.
What happened
FDA reviewed www.koreanfillers.com and found the site offering injectable botulinum toxin products, including Meditoxin Botulinum Toxin, Cosmetics Medi 2, and Meditoxin Botulinum Toxin 200U, for sale to U.S. consumers. FDA said the site claimed the products treat conditions such as essential blepharospasm, cerebral palsy, and post-stroke upper limb spasticity, which shows they are drugs. FDA said there are no approved applications for these products and that their labeling lacks adequate directions for use, making them unapproved and misbranded.
What FDA found
The website offers botulinum toxin drug products for sale in the U.S. without FDA-approved applications.
section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]The products are misbranded because their labeling does not give adequate directions for safe use by a layperson.
section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)]By offering the prescription drugs to U.S. consumers, the website causes misbranded drugs to enter interstate commerce.
section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]FDA treats the products as drugs and new drugs because they are intended to treat medical conditions and are not generally recognized as safe and effective.
sections 201(g) and 201(p) of the FD&C Act [21 U.S.C. §§ 321(g), 321(p)]
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers and to notify FDA in writing within 15 working days of steps taken to correct the violations and prevent recurrence.
Who should pay attention
- companies selling injectable cosmetic or therapeutic drugs online
- clinics and consumers buying imported botulinum toxin products
- distributors and websites offering foreign drug products in the U.S.
This is a summary. Read the original letter on fda.gov.